Entera Bio Ltd.
ENTX
Rank in Stocks
#11428
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase,... Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
Share Price
$3.25
Last synced: 2026-11-09
Market Cap
$565.25M
Change (1 day)
3.50%
Change (1 year)
11.68%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Entera Bio Ltd. (ENTX)
Category
Healthcare
EPS for Entera Bio Ltd. (ENTX)
EPS as of September 2026 TTM: $-0.17
According to Entera Bio Ltd.'s latest financial reports, its current EPS (TTM) is $-0.17. At the end of 2025 the company had an EPS of $-0.25, equal to its 2024 EPS of $-0.25.
EPS history for Entera Bio Ltd. from 2015 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.17 | -32.00% |
| 2025 | $-0.25 | 0.00% |
| 2024 | $-0.25 | -19.35% |
| 2023 | $-0.31 | -31.11% |
| 2022 | $-0.45 | -4.26% |
| 2021 | $-0.47 | -12.96% |
| 2020 | $-0.54 | -40.00% |
| 2019 | $-0.90 | -1.10% |
| 2018 | $-0.91 | -30.53% |
| 2017 | $-1.31 | 835.71% |
| 2016 | $-0.14 | -61.11% |
| 2015 | $-0.36 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -9,311.76% |
US
|
|
| $-7.07 | 4,058.82% |
US
|
|
| $-5.29 | 3,011.76% |
AU
|
|
| $12.88 | -7,676.53% |
BE
|
|
| $21.56 | -12,782.35% |
NL
|
Questions about Entera Bio Ltd.'s earnings per share (EPS)
What is Entera Bio Ltd.'s earnings per share (EPS)?
Entera Bio Ltd.'s earnings per share (EPS) over the last twelve months is $-0.17, as of Sep 2026.
What was Entera Bio Ltd.'s earnings per share (EPS) in 2025?
In 2025, Entera Bio Ltd.'s earnings per share (EPS) was $-0.25, compared with $-0.25 in 2024.
How has Entera Bio Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Entera Bio Ltd.'s earnings per share (EPS) was highest in 2025 ($-0.25) and lowest in 2020 ($-0.54).
How does Entera Bio Ltd.'s earnings per share (EPS) compare with similar companies?
Entera Bio Ltd.'s earnings per share (EPS) ($-0.17) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.